This paper analyzed the relationship between the early resolution of patent disputes and the patent linkage regime in United States and conducted research on the judicial application of “artificial infringement” under § 271(e)(2), the disputes and legal reasoning of United States courts in regard to the issues that whether the Paragraph Ⅳ statement is a necessary prerequisite to determine jurisdiction and whether to extend the infringement object to the later-issued patents. Based on the perception of the function of the mechanism for early resolution of patent disputes in the United States, the status quo of China's pharmaceutical reformation policy, its legislation and legal practice in the field of pharmaceuticals, this paper proposed a better path to build the dispute resolution mechanism under the ongoing drug patent linkage system in China, that is, to solve the patent disputes between the brand-name company and the generic drug company in the specific case related to disputes over confirming the absence of infringement on patent rights, and to provide opportunity for the drug patentees to petition administrative objections.